Do Multi-telomere Lengths Act as Joint Predictors of Prostate Cancer Survival?

Principal Investigator:
Ingrid Oakley-Girvan, Ph.D.
Co-Investigator:
David Rehkopf, Sc.D., and Alice Whittemore, Ph.D. (Stanford University)
Collaborators:
Funding Source:
Stanford Cancer Institute
Funding Period:
Study Website:

This study aims to provide important information to help decide how to treat prostate cancer, the most common malignancy in men.  In this study, we hope to use telomere length to improve how we classifying which men will die from their disease.  The aim is to reduce treatments with significant side effects in men that are unlikely to die of prostate cancer but to continue to provide treatment to men that have a high chance of dying from prostate cancer.

Publications:

© Cancer Prevention Institute of California